Latest News

SleepCogni to trial its ‘ground breaking’ behavioural treatment for insomnia

SleepCogni has announced it will trial its unique insomnia treatment, following a £575k interim fund raising round, which includes existing shareholders and a new Innovate UK biomedical catalyst award, bringing its total funding to £1.7m to date.

Source link




Related posts

Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session

Newsemia

Report Finds Americans' Health Is Flagging

Newsemia

Shelter Dog Dies 48 Hours After Adoption; Reportedly Diagnosed With Parvovirus

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy